Emory's Dr. Michael Schaufele on the pain associated with sciatica. Related Links Emory Orthopaedics...
A new study suggests that the current approach to treating peoples cholesterol is wrong. The finding...
Dr. Andrew Tutt - Breakthrough Breast Cancer Research Unit, Kings College London, UK A study reports...
ecancer.tv speaks to Professor Robert Coleman of the Cancer Research Centre, Academic Unit of Clinic...
This is a preview of Chemical Peels to Treat the Ageing Face by Combination Strategies and Contempor...
PubMed |
(0) (0 Votes)
|
Views: (1094) Date: (27-01-09) Pages: () |
Abstract: Anti-immunoglobulin treatment of murine B-cell lymphomas induces active transforming growth factor beta but pRB hypophosphorylation is transforming growth factor beta independent. Warner GL, Ludlow JW, Nelson DA, Gaur A, Scott DW. Division of Immunology and Immunotherapy, University of Rochester Cancer Center, New York 14642. Cross-linkin g of B-cell membrane immunoglobulin (Ig) receptors induces growth arrest at G1-S, leading to apoptosis and cell death in the immature lymphomas WEHI-231 and CH31, but not in the CH12 B-cell line. In this system, which has been used as a model for B-cell tolerance, we have established that these lymphomas produce active transforming growth factor beta (TGF-beta) when treated with anti-Ig and that their hierarchy of sensitivity to TGF-beta generally correlates with their growth inhibition by anti-Ig. TGF-beta, in turn, has been shown to interfere with the phosphorylation of the retinoblastoma gene product, pRB. Herein, we also demonstrate that in WEHI-231 B-lymphoma cells treated with anti-Ig for 24 h, the pRB protein is found to be predominantly in the underphosphorylated form, as previously reported for cells arrested by the exogenous addition of TGF-beta. However, neutralizing antibodies to TGF-beta failed to prevent growth inhibition by anti-Ig in WEHI-231 and CH31. When WEHI-231 lymphoma cells were selected for growth in TGF-beta, the majority of the TGF-beta-resistant clones remained sensitive to anti-Ig-mediated growth inhibition. In these clones, the retinoblastoma gene product was found to be in the underphosphorylated form after 24-h treatment with anti-Ig, but not with TGF-beta. These data show that anti-Ig treatment of murine B-cell lymphomas stimulates the production of active TGF-beta but that a TGF-beta-independent pathway may be responsible for the pRB underphosphorylation and cell cycle blockade. PMID: 1633108 [PubMed - indexed for MEDLINE]